SARS-CoV-2 Mpro-IN-57 

SARS-CoV-2 Mpro-IN-57 is an irreversible SARS-CoV-2 main protease inhibitor with an IC₅₀ of 0.41 μM and a K_d of 247.37 nM. SARS-CoV-2 Mpro-IN-57 forms a covalent bond with the key amino acid residue Cys145 in SARS-CoV-2 main protease via its -CN group. SARS-CoV-2 Mpro-IN-57 can be used for the research of COVID-19^[1].

SARS-CoV-2 Mpro-IN-57 (compound 3ab) (15 min) potently inhibits purified recombinant SARS-CoV-2 Mpro, with an IC₅₀ of 0.41 μM, and achieves complete inhibition at a concentration of 100 μM^[1].
SARS-CoV-2 Mpro-IN-57 forms a covalent bond with the Cys145 residue of SARS-CoV-2 Mpro, while forming an auxiliary hydrogen bond with His41 and a Pi-alkyl interaction with Met49^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

279.15

C₁₁H₈N₂O₂Se

3031240-80-6

O=C(OC)C1(N=C1C2=CC=CC=C2)[Se]C#N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang X, et al. Discovery of 3-phenyl-2H-aziridine derivatives as potent irreversible inhibitors of SARS-CoV-2 main protease via enzyme kinetics and microscale thermophoresis. Bioorg Chem. 2026 Jul 5;175:109800.  [Content Brief]